• Biodesix® Announces Additional Data in Phase III Lung Cancer Diagnostic Study

    October 28, 2013 Biodesix, Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced additional data from the Phase III clinical trial for its serum protein test, VeriStrat®. Results were presented at the 15thWorld Conference on Lung Cancer in Sydney, Australia. “PROSE data ... Read more
  • Biodesix Secures Medicare Coverage for VeriStrat Test

    June 20, 2013 Coverage of Predictive Biomarker Test Enables Lung Cancer Patients to Benefit From More-Informed Treatment Decisions Biodesix, Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced that Novitas Solutions, the Medicare Administrative Contractor for the region that includes Colorado, has established coverage for the company’s VeriStrat test. VeriStrat, a clinically validated blood-based ... Read more
  • Biodesix Announces Results in Phase III Lung Cancer Diagnostic Study; First Prospective Biomarker-Stratified Validation Study in Oncology

    June 3, 2013 Results of independent trial confirm VeriStrat’s ability to predict differential treatment outcomes between erlotinib and chemotherapy Biodesix, Inc., a fully integrated molecular diagnostics company dedicated to personalizing medicine, today announced results of the recently completed phase III clinical trial for its VeriStrat® test. ... Read more
  • Biodesix to Announce Results of VeriStrat® Biomarker Study

    May 21, 2013 Independent Phase III Data to Be Presented at the 2013 ASCO Annual Meeting Biodesix, Inc., announced that final results of the first completed biomarker-stratified, validation study in oncology will be presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31st – June 4th, 2013. The Randomized Proteomic Stratified Phase III ... Read more
  • Biodesix Closes Series D Financing

    April 12, 2013 Biodesix, Inc., a molecular diagnostics company advancing the development of innovative products for personalizing medicine, announced today that the company closed on $8.8 million in a follow-on sale of its Series D preferred shares.  All funds were provided by existing shareholders of the company.  The investment will be used for ongoing ... Read more
  • Peer-Reviewed Study Confirms VeriStrat® Test from Biodesix Provides Useful Information for Physicians in Managing Patients with Lung Cancer

    April 2, 2013 Physicians Adopting Novel Serum Test to Help Recommend Course of Treatment for Patients with Advanced Disease Biodesix, Inc., a molecular diagnostic company dedicated to personalizing medicine, today announced the online release of a peer-reviewed study demonstrating that physicians are using the company’s VeriStrat test to help guide treatment decisions for patients with advanced non-small ... Read more
  • Biodesix’ Heinrich Roder Presents at 2013 Biomarker Summit

    March 18, 2013 Session Examines Use of Circulating Proteins to Define Novel Disease States Biodesix, Inc., a fully integrated molecular diagnostics company dedicated to personalizing medicine, today announced that Chief Technology Officer Heinrich Roder, DPhil will present at the 6th Oncology Biomarkers Conference as part of the 2013 Biomarker Summit taking ... Read more
  • VeriStrat® Provides Oncologists with More Information to Personalize Therapy for Elderly Patients With Lung Cancer

    February 20, 2013 Data Published in Journal of Thoracic Oncology A new study published online ahead of print in the Journal of Thoracic Oncology concludes that Biodesix’ VeriStrat test was predictive of survival outcomes between erlotinib and gemcitabine. The study, “A Retrospective Analysis of VeriStrat Status on Outcome of a Randomized Phase II Trial of ... Read more
  • VeriStrat® Test Predicts Differential Treatment Benefit between Chemotherapy and Targeted Therapy for Lung Cancer Patients

    September 6, 2012 Encouraging New Data Presented at Chicago Multidisciplinary Symposium in Thoracic Oncology Results from the VeriStrat analysis of serum or plasma samples taken from a Phase II study evaluating erlotinib, gemcitabine, and erlotinib plus gemcitabine in elderly advanced NSCLC patients were presented today  at the Chicago Multidisciplinary Symposium  in Thoracic Oncology. ... Read more
  • Biodesix Closes Series D Financing

    August 29, 2012 Biodesix, Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, has closed on a $12 million extension to its Series D financing. The new capital will support commercialization activities for the Company’s first product VeriStrat®, a blood-based test that helps physicians guide treatment for patients with non-small cell lung cancer ... Read more